OrbusNeich Recognized as a 2026 Top Employer

(Hong Kong, June 12, 2026) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional solutions for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, has been recognized as a “2026 Top Employer”, organized by 51job.

This recognition affirms the Group’s excellence in talent strategy, diversity and inclusion, and sustainable corporate development. It also highlights the Group’s strong ability to attract, develop, and retain global talent, further reinforcing its position as an employer of choice in the medical device industry.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “At OrbusNeich, we see our people as our most valuable asset and are committed to fostering a culture where our people can thrive and drive innovation. We continuously enhance employee care, build globally competitive organizational capabilities, and give back to society, with the goal of strengthening employee well-being and creativity. These efforts enable us to build a vibrant, high-performing team, attract and retain exceptional talent, and continue delivering life-changing solutions to physicians and patients around the world.”

The “2026 Top Employer” list was officially released by 51job, a leading human resources service provider in China, following months of rigorous evaluation and in-depth research. This year, the award honors 400 outstanding organizations selected from an initial pool of 6,000 companies, drawn from tens of thousands of active employers across China. It recognizes businesses that have demonstrated excellence in strategic transformation, AI-enabled empowerment, employer branding, and full-lifecycle talent management.

OrbusNeich recognized as a 2026 Top Employer by 51job

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.